- Home
- AGIO vs SYNA Comparison
AGIO vs SYNA Comparison
Compare AGIO & SYNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGIO
- SYNA
- Stock Information
- Founded
- AGIO 2007
- SYNA 1986
- Country
- AGIO United States
- SYNA United States
- Employees
- AGIO N/A
- SYNA N/A
- Industry
- AGIO Biotechnology: Pharmaceutical Preparations
- SYNA Computer peripheral equipment
- Sector
- AGIO Health Care
- SYNA Technology
- Exchange
- AGIO Nasdaq
- SYNA Nasdaq
- Market Cap
- AGIO 2.5B
- SYNA 2.7B
- IPO Year
- AGIO 2013
- SYNA 2002
- Fundamental
- Price
- AGIO $24.46
- SYNA $58.86
- Analyst Decision
- AGIO Buy
- SYNA Strong Buy
- Analyst Count
- AGIO 7
- SYNA 7
- Target Price
- AGIO $37.33
- SYNA $89.71
- AVG Volume (30 Days)
- AGIO 1.8M
- SYNA 434.4K
- Earning Date
- AGIO 10-30-2025
- SYNA 11-06-2025
- Dividend Yield
- AGIO N/A
- SYNA N/A
- EPS Growth
- AGIO N/A
- SYNA N/A
- EPS
- AGIO N/A
- SYNA N/A
- Revenue
- AGIO $44,791,000.00
- SYNA $1,109,100,000.00
- Revenue This Year
- AGIO $25.57
- SYNA $11.05
- Revenue Next Year
- AGIO $153.24
- SYNA $11.32
- P/E Ratio
- AGIO N/A
- SYNA N/A
- Revenue Growth
- AGIO 36.26
- SYNA 13.24
- 52 Week Low
- AGIO $22.24
- SYNA $41.80
- 52 Week High
- AGIO $62.45
- SYNA $89.81
- Technical
- Relative Strength Index (RSI)
- AGIO 25.59
- SYNA 30.37
- Support Level
- AGIO $22.24
- SYNA $62.24
- Resistance Level
- AGIO $46.00
- SYNA $69.90
- Average True Range (ATR)
- AGIO 2.20
- SYNA 2.59
- MACD
- AGIO -1.86
- SYNA -1.09
- Stochastic Oscillator
- AGIO 8.76
- SYNA 0.62
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
About SYNA Synaptics Incorporated $0.001 Par Value
Synaptics Inc is a producer of semiconductor solutions for the mobile, PC, and Internet of Things markets. The company develops human interface solutions that enable touch, display, fingerprint, video, audio, voice, AI, and connectivity functions for smartphones, PCs, Internet of Things products, and other electronic devices. It operates in one segment: the development, marketing, and sale of semiconductor products used in electronic devices and products. The company geographically, it derives a majority of revenue from China, and also has its presence in Taiwan, Japan, South Korea, United States and Other countries.